Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland;
Department of Pathology, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
Cancer Genomics Proteomics. 2022 Sep-Oct;19(5):556-569. doi: 10.21873/cgp.20340.
BACKGROUND/AIM: Mutational signatures reflect common patterns based on the counts of mutations and their sequence context. The prognostic value of these signatures, mirroring various carcinogenetic processes of cancers, are unexplored in gastrointestinal cancers. Our aim was to evaluate possible prognostic relevance of mutational signatures in gastrointestinal carcinomas after adjusting with the traditional prognostic factors.
We used publicly available data from The Cancer Genome Atlas and Pan-Cancer Analysis of Whole Genomes to evaluate the associations between survival endpoints and activity of mutational signatures in seven types of gastrointestinal cancers.
Most strikingly, the high activity of age-related single-base substitution 5 (SBS5) and SBS40 signatures were in rectal adenocarcinomas associated with both improved overall survival (OS) [for SBS5 hazard ratio (HR) 0.130; 95% CI=0.03-0.56, for SBS40 HR=0.072; 95% CI=0.012-0.44, respectively] and similarly also to rectal cancer-specific survival. In patients with left-sided (but not right-sided) colon adenocarcinoma, the high activity of SBS2 signatures, formed due to APOBEC activity, predicted shortened OS. In pancreatic cancer, the high activity of SBS10b, caused by polymerase epsilon exonuclease proofreading defects, was associated both with longer OS (HR=0.44; 95% CI=0.205-0.96) and pancreatic cancer-specific survival (HR=0.32; 95% CI=0.112-0.91).
Several mutational signatures seem to have clinically meaningful, cancer-specific associations with prognosis among gastrointestinal cancers.
背景/目的:突变特征反映了基于突变数量及其序列背景的常见模式。这些特征的预后价值反映了癌症的各种致癌过程,但在胃肠道癌症中尚未得到探索。我们的目的是在调整传统预后因素后,评估突变特征在胃肠道癌中的可能预后相关性。
我们使用来自癌症基因组图谱和全基因组泛癌分析的公开可用数据,评估了七种胃肠道癌的生存终点与突变特征活性之间的关联。
最引人注目的是,直肠腺癌中与整体生存(OS)改善相关的年龄相关单碱基替换 5(SBS5)和 SBS40 特征的高活性[对于 SBS5 危险比(HR)为 0.130;95%置信区间(CI)为 0.03-0.56,对于 SBS40 HR 为 0.072;95%CI=0.012-0.44],同样与直肠癌特异性生存相关。在左侧(而非右侧)结肠癌患者中,APOBEC 活性引起的 SBS2 特征的高活性预测 OS 缩短。在胰腺癌中,由于聚合酶 epsilon 外切核酸酶校对缺陷引起的 SBS10b 高活性与 OS 延长(HR=0.44;95%CI=0.205-0.96)和胰腺癌特异性生存(HR=0.32;95%CI=0.112-0.91)均相关。
几种突变特征似乎与胃肠道癌的预后具有癌症特异性的临床意义关联。